Heron Therapeutics, Inc.
Heron Therapeutics, Inc. (0J4V.L) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Heron Therapeutics, Inc. (0J4V.L), covering cash flow, earnings, and balance sheets.
Heron Therapeutics, Inc. (0J4V.L) Income Statement & Financial Overview
Access detailed annual and quarterly income data for Heron Therapeutics, Inc. 0J4V.L financial performance.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $40.78M | $42.27M | $36.02M | $34.67M |
| Cost of Revenue | $10.23M | $18.92M | $10.52M | $8.44M |
| Gross Profit | $30.55M | $23.35M | $25.51M | $26.23M |
| Gross Profit Ratio | $0.75 | $0.55 | $0.71 | $0.76 |
| R&D Expenses | $3.18M | $4.46M | $4.43M | $4.61M |
| SG&A Expenses | $23.20M | $23.34M | $27.52M | $26.42M |
| Operating Expenses | $26.38M | $27.81M | $31.95M | $31.02M |
| Total Costs & Expenses | $36.61M | $46.73M | $42.47M | $39.47M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $581000.00 | $0.00 | $641000.00 | $689000.00 |
| EBITDA | $8.73M | -$4.46M | -$5.80M | -$4.11M |
| EBITDA Ratio | $0.21 | -$0.11 | -$0.16 | -$0.12 |
| Operating Income | $4.17M | -$4.46M | -$6.45M | -$4.80M |
| Operating Income Ratio | $0.10 | -$0.11 | -$0.18 | -$0.14 |
| Other Income/Expenses (Net) | -$510000.00 | -$390000.00 | -$2.79M | $1.64M |
| Income Before Tax | $3.66M | -$4.85M | -$9.23M | -$3.16M |
| Income Before Tax Ratio | $0.09 | -$0.11 | -$0.26 | -$0.09 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $645724.00 |
| Net Income | $3.66M | -$4.85M | -$9.23M | -$3.16M |
| Net Income Ratio | $0.09 | -$0.11 | -$0.26 | -$0.09 |
| EPS | $0.02 | -$0.03 | -$0.06 | -$0.02 |
| Diluted EPS | $0.02 | -$0.03 | -$0.06 | -$0.02 |
| Weighted Avg Shares Outstanding | $153.15M | $152.83M | $152.31M | $151.20M |
| Weighted Avg Shares Outstanding (Diluted) | $153.15M | $152.83M | $152.31M | $151.20M |
The company's financials show resilient growth, with revenue advancing from $34.67M in Q1 2024 to $40.78M in Q4 2024. Gross profit remained healthy with margins at 75% in Q4 2024 compared to 76% in Q1 2024. Operating income hit $4.17M last quarter, sustaining a consistent 10% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $8.73M. Net income rose to $3.66M, while earnings per share reached $0.02. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan